

Public Assessment Report

Scientific discussion

Cetirizine diHCl Aurobindo 10 mg, film-coated tablets (cetirizine dihydrochloride)

NL/H/5909/001/DC

Date: 10 April 2024

This module reflects the scientific discussion for the approval of Cetirizine diHCl Aurobindo 10 mg, film-coated tablets. The procedure was finalised at 18 May 2016 in Portugal (PT/H/1483/01/DC). After a transfer on 17 November 2023, the current RMS is the Netherlands. For information on changes after this date please refer to the 'steps taken after finalisation' at the end of this PAR.

List of abbreviations

ASMF	Active Substance Master File
CEP	Certificate of Suitability to the monographs of the European Pharmacopoeia
CHMP	Committee for Medicinal Products for Human Use
CMD(h)	Coordination group for Mutual recognition and Decentralised procedure for human medicinal products
CMS	Concerned Member State
EDMF	European Drug Master File
EDQM	European Directorate for the Quality of Medicines
EEA	European Economic Area
EMA	European Medicines Agency
ERA	Environmental Risk Assessment
ICH	International Conference of Harmonisation
MAH	Marketing Authorisation Holder
Ph.Eur.	European Pharmacopoeia
PL	Package Leaflet
RH	Relative Humidity
RMP	Risk Management Plan
RMS	Reference Member State
SmPC	Summary of Product Characteristics
TSE	Transmissible Spongiform Encephalopathy

I. INTRODUCTION

Aurobindo Pharma B.V., the Netherlands has applied for a marketing authorisation for Cetirizine diHCl Aurobindo 10 mg, film-coated tablets, containing cetirizine dihydrochloride as the active substance, indicated for the relief of nasal and ocular symptoms of seasonal and perennial rhinitis and for the relief of symptoms of chronic idiopathic urticaria.

A comprehensive description of the up-to-date indications and posology is given in the SmPC.

This application concerns a generic application claiming essential similarity with the reference product Zyrtec 10 mg, film-coated tablets, from UCB Pharma, registered since 1989.

The marketing authorization was granted on 07-06-2016 based on Directive 2001/83/EC article 10.1 (a) (iii) first paragraph and the Marketing Authorisation Holder is Aurobindo Pharma B.V.

The concerned member state (CMS) involved in this procedure is Belgium.

This type of application refers to information that is contained in the pharmacological-toxicological and clinical part of the dossier of the authorisation of the reference product. A reference product is a medicinal product authorised and marketed on the basis of a full dossier, i.e. including chemical, biological, pharmaceutical, pharmacological-toxicological and clinical data. This information is not fully available in the public domain. Authorisations for generic products are therefore linked to the 'original' authorized medicinal product, which is legally allowed once the data protection time of the dossier of the reference product has expired. For this kind of application, it has to be demonstrated that the pharmacokinetic profile of the product is similar to the pharmacokinetic profile of the reference product. This generic product can be used instead of its reference product.

II. QUALITY ASPECTS

II.1 Introduction

The medicinal product has the trade name of Cetirizine diHCl Aurobindo 10 mg, film-coated tablets, containing cetirizine dihydrochloride as the active substance. Cetirizine diHCl Aurobindo are white to off-white, off-rectangular film-coated tablets, with a score line in one side (dividing 2 from 0) and X in the other side. The tablet can be divided into equal doses.

The film-coated tablets are supplied in PVC/PVDC-Aluminium blisters, in carton boxes containing 10, 20, 30, 50 and 100 film-coated tablets. The film-coated tablets are supplied also in HDPE bottles, in carton boxes containing 250 film-coated tablets.

The excipients are:


- Core: Lactose monohydrate, Cellulose, microcrystalline, croscarmellose sodium, Silica,

colloidal anhydrous, Magnesium Stearate

- Coating: Hypremellose 5 cP, Polydextrose, Titanium Dioxide E171, Macrogol 400

II.2 Drug Substance

Cetirizine dihydrochloride



The active substance cetirizine is white or almost white powder.

Solubility: Freely soluble in water, practically insoluble in Acetone and in Methylene chloride.

Hygroscopicity: slightly hygroscopic

Polymorphism: Crystalline Polymorph

Isomerism: cetirizine has one chiral centre and exhibits Isomerism. Cetirizine is a racemic mixture.

Quality control of drug substance

The specifications for routine controls of cetirizine are in line with requirements of current edition of European Pharmacopoeia.

II.3 Medicinal Product

Pharmaceutical development

The development of the product has been described.

Manufacturing process

The documentation provided complies with relevant EU guidelines and directives. Manufacture is performed in accordance with cGMP and consistency in quality and homogeneity is demonstrated.

Control of excipients

The development of the product has been described, the choice of excipients is justified and their functions explained.

Quality control of drug product

The finished product specification is based on relevant development and stability studies. Appropriate validation data have been provided for the analytical methods. Batch analyses data support the proposed finished product specification.

Stability of drug product

Stability studies were performed in line with the ICH guidance. The proposed shelf-life of 36 months, without any special storage conditions for the drug product is considered acceptable.

III. NON-CLINICAL ASPECTS

Pharmacodynamic, pharmacokinetic and toxicological properties of cetirizine dihydrochloride are well known. As cetirizine dihydrochloride are widely used, well-known active substances, the applicant has not provided additional studies and further studies are not required. An overview based on literature review is, thus, appropriate.

III.1 Ecotoxicity/environmental risk assessment (ERA)

Since Cetirizine diHCl Aurobindo is intended for generic substitution, this will not lead to an increased exposure to the environment.

IV. CLINICAL ASPECTS

IV.1 Introduction

To support the application, the applicant has submitted one study report describing bioequivalence study (Study Code: A189-11).

IV.2 Pharmacovigilance System

The RMS considers that the Pharmacovigilance system (version SPS/AUROVITAS- PT/002 date 26 May 2015), as described by the applicant fulfils the requirements and provides adequate evidence that the applicant has the services of a qualified person responsible for pharmacovigilance and has the necessary means for the notification of any adverse reaction suspected of occurring either in the Community or in a third country. The appointed EU-QPPV is LudkaFyles (MD) from Aurobindo Pharma Limited who resides in the UK. The pharmacovigilance system master file (PSMF no.MFL1655) is located at the following address: Ares, Odyssey Business Park, West End Road, South Ruislip, Middlesex. HA4 6QD - UK . The local contact person for Pharmacovigilance for Portugal is Rita Prazeres (MD), from Aurovitas, Unipessoal, Lda.

IV.3 Risk Management Plan

A new version of the RMP (version 3.0 dated 29-03-2016) was submitted by the Applicant. This version is accepted.

V. USER CONSULTATION

The readability of the package leaflet was successfully demonstrated.

VI. OVERALL CONCLUSION, BENEFIT/RISK ASSESSMENT AND RECOMMENDATION

The application for Cetirizine diHCl Aurobindo 10 mg, film-coated tablets contains adequate quality, non-clinical and clinical data and bioequivalence has been shown. A benefit/risk ratio comparable to the reference product can therefore be concluded.

**STEPS TAKEN AFTER THE FINALISATION OF THE INITIAL PROCEDURE -
SUMMARY**

Procedure number	Scope	Product Information affected	Date of end of procedure	Approval/ non approval	Summary/ Justification for refuse
1051800	RMS Transfer PT/H/1483/01/ DC to NL/H/5909/001 /DC	Yes	17 November 2023	Approved	N.A.